← Back to Search

Monoclonal Antibodies

Multiple Sclerosis group 1 for Multiple Sclerosis

N/A
Recruiting
Led By John DeLuca, PhD
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured for change at 3 time points for change (before, six months and 12 months after intervention)
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is studying how well disease-modifying medicines work in treating cognitive fatigue in people with RRMS.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured for change at 3 time points (before, six months and 12 months after intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured for change at 3 time points (before, six months and 12 months after intervention) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Brain activation (BOLD signal)
Secondary study objectives
Fatigue onset

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Multiple Sclerosis group 2Experimental Treatment0 Interventions
Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
Group II: Multiple Sclerosis group 1Experimental Treatment1 Intervention
Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
Group III: Healthy ControlsExperimental Treatment0 Interventions
Healthy individuals who are age, gender and education matched to the other groups.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ocrelizumab
FDA approved

Find a Location

Who is running the clinical trial?

Kessler FoundationLead Sponsor
180 Previous Clinical Trials
10,999 Total Patients Enrolled
33 Trials studying Multiple Sclerosis
1,597 Patients Enrolled for Multiple Sclerosis
Hackensack Meridian HealthOTHER
135 Previous Clinical Trials
30,242 Total Patients Enrolled
1 Trials studying Multiple Sclerosis
60 Patients Enrolled for Multiple Sclerosis
John DeLuca, PhDPrincipal InvestigatorKessler Foundation
2 Previous Clinical Trials
100 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
100 Patients Enrolled for Multiple Sclerosis
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top